Stock DYN DYNE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Dyne Therapeutics, Inc.

Equities

DYN

US26818M1080

Real-time Estimate Cboe BZX
Other stock markets
 11:54:49 2024-05-28 am EDT 		5-day change 1st Jan Change
30.44 USD -2.50% Intraday chart for Dyne Therapeutics, Inc. -6.65% +129.02%
May. 23 Dyne Therapeutics Insider Sold Shares Worth $1,002,751, According to a Recent SEC Filing MT
May. 22 Dyne Therapeutics Prices $325.5 Million Common Stock Offering MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
GL
Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock
GL
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
GL
Dyne Therapeutics : ACHIEVE & DELIVER Clinical Update Presentation
PU
Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints
GL
Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ET
AQ
Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ET
GL
Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
GL
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer
GL
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium
GL
Dyne Therapeutics Announces CEO Transition
GL
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days
GL
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days
AQ
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
GL
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
AQ
Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference
GL
Dyne Therapeutics to Present at February Investor Conferences
GL
Dyne Therapeutics to Present at February Investor Conferences
AQ
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
GL
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DYN Stock
  4. News Dyne Therapeutics, Inc.
  5. Press Releases